Marianne Dibrino

Array ( [id] => 15649671 [patent_doc_number] => 20200087365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => IMPROVED LAMP CONSTRUCTS COMPRISING CANCER ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/610133 [patent_app_country] => US [patent_app_date] => 2018-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41048 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13397747 [patent_doc_number] => 20180250416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 15/967465 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15967465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519661 [patent_doc_number] => 20180311373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => CONJUGATE MOLECULE [patent_app_type] => utility [patent_app_number] => 15/965496 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134779 [patent_doc_number] => 11560432 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Monoclonal antibodies directed to peptide in the context of MHC and methods of making and using monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 15/952965 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 46 [patent_no_of_words] => 19400 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15952965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15529485 [patent_doc_number] => 20200057048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => ASSAY TO MEASURE THE POTENCY OF RECEPTOR-LIGAND INTERACTIONS IN NANOMEDICINES [patent_app_type] => utility [patent_app_number] => 16/603180 [patent_app_country] => US [patent_app_date] => 2018-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536639 [patent_doc_number] => 20180319863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => ANTI-HLA ASSAY AND METHODS [patent_app_type] => utility [patent_app_number] => 15/944595 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15944595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345271 [patent_doc_number] => 20200010527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => Antigen Discovery for T Cell Receptors Isolated from Patient Tumors Recognizing Wild-Type Antigens and Potent Peptide Mimotopes [patent_app_type] => utility [patent_app_number] => 16/492898 [patent_app_country] => US [patent_app_date] => 2018-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16492898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519571 [patent_doc_number] => 20180311328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Peptide Selection Method [patent_app_type] => utility [patent_app_number] => 15/926637 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15926637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13510525 [patent_doc_number] => 20180306805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS [patent_app_type] => utility [patent_app_number] => 15/914808 [patent_app_country] => US [patent_app_date] => 2018-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15914808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425105 [patent_doc_number] => 20180264095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => POPULATION-BASED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM [patent_app_type] => utility [patent_app_number] => 15/910965 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425103 [patent_doc_number] => 20180264094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => PERSONALISED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM [patent_app_type] => utility [patent_app_number] => 15/910930 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12889288 [patent_doc_number] => 20180188271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => METHOD OF SCREENING MHC MOLECULES [patent_app_type] => utility [patent_app_number] => 15/902791 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527225 [patent_doc_number] => 20200055918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/487604 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13301135 [patent_doc_number] => 20180202104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => STANDARDIZED EX VIVO PLATFORMS FOR THE ANTIGEN-SPECIFIC EXPANSION OF CD4+ T CELL POPULATIONS [patent_app_type] => utility [patent_app_number] => 15/895734 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12858133 [patent_doc_number] => 20180177885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => Recombinant Vaccines and Use Thereof [patent_app_type] => utility [patent_app_number] => 15/895402 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17267546 [patent_doc_number] => 11192958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease [patent_app_type] => utility [patent_app_number] => 15/895782 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 36 [patent_no_of_words] => 32220 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18369134 [patent_doc_number] => 11649288 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents [patent_app_type] => utility [patent_app_number] => 16/480833 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 22 [patent_no_of_words] => 81918 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16480833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13329063 [patent_doc_number] => 20180216069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => COMPOSITIONS AND METHODS FOR REGULATING NK CELL ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/876839 [patent_app_country] => US [patent_app_date] => 2018-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297525 [patent_doc_number] => 20180200299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => POLYCLONAL GAMMA DELTA T CELLS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/872354 [patent_app_country] => US [patent_app_date] => 2018-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15872354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769390 [patent_doc_number] => 11401318 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Multimeric polypeptides of HLA-G including at least two alpha3 domains and pharmaceutical uses thereof [patent_app_type] => utility [patent_app_number] => 15/868119 [patent_app_country] => US [patent_app_date] => 2018-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7485 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15868119 [rel_patent_id] =>[rel_patent_doc_number] =>)